SYMBOL:

    Up to 100 tickers separated by a space .....Watch Post-Market activities
Site Map FAQ Contact us Home Personalize
Company
Industry
Earnings
US Markets
Most Active
Portfolio
Tools
ETFs
Ratings
TETRAPHASE PHARMACEUTICALS INC
(NQNM:TTPH Last Sale: 1.26 +0)
Fundamentals Charts Tech Analysis Industry Earnings
Company Profile   Details

Company Web Site
NQNM: (TTPH : $1.26)
$9,147 million Market Cap at Market Close, July 1, 2022
Biomedics SubIndustry up .00% / Health Industry up .00% Today
Research Report Earnings Snapshot - Last 11/10/18
Fact Sheet
Financial Statements
Peer Comparison
Annual Reports

L. Patrick Gage, Chmn., Garen Bohlin, CEO
Focus is new antibiotics, the creation of tetracycline drugs that have the potential to reinvigorate the clinical and market potential of the class. Novel antibiotics for serious and life-threatening multi-drug resistant infections. Lead product candidate, eravacycline, is a synthetic tetracycline derivative being developed as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. IPO at $7 March 20, 2013. Raised $75 million, selling 10.7 million shares, 54% of the outstanding. Lead Manager: Barclays.
Historical Charts    Technical Analysis
No Historical Data available for TTPH

Type of Stock Symbol Last Sale Last Close Net +/- % +/- Low High Volume 52wk Low 52wk High Shares(M)
Common TTPH $1.26 $1.26 0 .0 $1.26 $1.32 30,175 $1.26 $1.32 7,259,236
Capitalization
Earnings Summary ()
*** No Earnings Available***
-10126
Common Stock $9,146,637

A
Google



QUICK NAVIGATION SITE SEARCH   Enter Keyword:
   
Home    Subscribe    Browser Help    Subscriber Services    B-to-B    Banks    Brokerage    Telco    Site Map    Legal    Contact/Email
Copyright © 1996 - 2025 Stock Smart with all rights reserved
Feed is currently being brought back up
Provided by Nanex